Short answer
LifeMD, Inc. (LFMD) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Forward-looking disclosure on XYOSTED self-pay program launch timing, pricing, scope, demand, and patient access.
LifeMD, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Forward-looking disclosure on XYOSTED self-pay program launch timing, pricing, scope, demand, and patient access
- Collaboration with Halozyme includes promotional and consumer-education initiatives
- Program availability and expansion subject to commercial adoption and telehealth prescribing regulations
- Controlled-substance telehealth, pharmacy, and promotional compliance risks could affect execution
Item EX-99.1 · Exhibit EX-99.1
- Exclusive telehealth co-marketing partnership with Antares Pharma for XYOSTED self-pay program
- July 2026 launch across 37 states, with LifeMD clinicians evaluating patients and pharmacy handling home delivery
- Approximately $249 monthly price includes medication, virtual care, laboratory diagnosis, follow-up, and refills without insurance
- Potential growth avenue in men’s health, but expansion depends on controlled-substance prescribing rules and patient adoption
- XYOSTED carries meaningful safety and compliance risks, including blood-pressure increases and Schedule III controlled-substance status
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LifeMD, Inc. 8-K filings
Get the next LFMD 8-K as it lands
Follow LFMD for push alerts, or ask the research agent what this filing means.